guest ::
| Home > Publications database > Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy. > print |
| Home > Publications database > Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy. > print |
| 001 | 127576 | ||
| 005 | 20240228140937.0 | ||
| 024 | 7 | _ | |a 10.15252/emmm.201404837 |2 doi |
| 024 | 7 | _ | |a pmid:26070712 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC4551343 |2 pmc |
| 024 | 7 | _ | |a 1757-4676 |2 ISSN |
| 024 | 7 | _ | |a 1757-4684 |2 ISSN |
| 024 | 7 | _ | |a altmetric:4140783 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-03599 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Stoy, Christian |0 P:(DE-HGF)0 |b 0 |e First author |
| 245 | _ | _ | |a Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy. |
| 260 | _ | _ | |a Weinheim |c 2015 |b Wiley-VCH |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1508324149_30731 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer fatalities in Western societies, characterized by high metastatic potential and resistance to chemotherapy. Critical molecular mechanisms of these phenotypical features still remain unknown, thus hampering the development of effective prognostic and therapeutic measures in PDAC. Here, we show that transcriptional co-factor Transducin beta-like (TBL) 1 was over-expressed in both human and murine PDAC. Inactivation of TBL1 in human and mouse pancreatic cancer cells reduced cellular proliferation and invasiveness, correlating with diminished glucose uptake, glycolytic flux, and oncogenic PI3 kinase signaling which in turn could rescue TBL1 deficiency-dependent phenotypes. TBL1 deficiency both prevented and reversed pancreatic tumor growth, mediated transcriptional PI3 kinase inhibition, and increased chemosensitivity of PDAC cells in vivo. As TBL1 mRNA levels were also found to correlate with PI3 kinase levels and overall survival in a cohort of human PDAC patients, TBL1 was identified as a checkpoint in the malignant behavior of pancreatic cancer and its expression may serve as a novel molecular target in the treatment of human PDAC. |
| 536 | _ | _ | |a 311 - Signalling pathways, cell and tumor biology (POF3-311) |0 G:(DE-HGF)POF3-311 |c POF3-311 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a TBL1X protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Tbl1x protein, mouse |2 NLM Chemicals |
| 650 | _ | 7 | |a Transducin |0 EC 3.6.5.1 |2 NLM Chemicals |
| 700 | 1 | _ | |a Sundaram, Aishwarya |0 P:(DE-He78)81661d885b9d708589e84a280d2796d4 |b 1 |u dkfz |
| 700 | 1 | _ | |a Rios Garcia, Marcos |0 P:(DE-He78)34a94db0c76003e41d389cca7e4c0826 |b 2 |u dkfz |
| 700 | 1 | _ | |a Wang, Xiaoyue |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Seibert, Oksana |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Zota, Annika |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Wendler, Susann |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Männle, David |b 7 |
| 700 | 1 | _ | |a Hinz, Ulf |b 8 |
| 700 | 1 | _ | |a Sticht, Carsten |b 9 |
| 700 | 1 | _ | |a Muciek, Maria |b 10 |
| 700 | 1 | _ | |a Gretz, Norbert |b 11 |
| 700 | 1 | _ | |a Rose, Adam J |b 12 |
| 700 | 1 | _ | |a Greiner, Vera |0 P:(DE-HGF)0 |b 13 |
| 700 | 1 | _ | |a Hofmann, Thomas |0 P:(DE-He78)99ae95278bd95e30462a4fb2d12026c6 |b 14 |u dkfz |
| 700 | 1 | _ | |a Bauer, Andrea |0 P:(DE-He78)f8c334e84e585d7fa09d4d4b2d322041 |b 15 |u dkfz |
| 700 | 1 | _ | |a Hoheisel, Jörg |0 P:(DE-He78)c684a26e52cc44716354a4d15f530b4e |b 16 |u dkfz |
| 700 | 1 | _ | |a Berriel Diaz, Mauricio |0 P:(DE-HGF)0 |b 17 |
| 700 | 1 | _ | |a Gaida, Matthias M |b 18 |
| 700 | 1 | _ | |a Werner, Jens |b 19 |
| 700 | 1 | _ | |a Schafmeier, Tobias |b 20 |
| 700 | 1 | _ | |a Strobel, Oliver |0 P:(DE-HGF)0 |b 21 |
| 700 | 1 | _ | |a Herzig, Stephan |0 P:(DE-He78)e527f794b23172e769c8904180546f57 |b 22 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.15252/emmm.201404837 |g Vol. 7, no. 8, p. 1048 - 1062 |0 PERI:(DE-600)2485479-7 |n 8 |p 1048 - 1062 |t EMBO molecular medicine |v 7 |y 2015 |x 1757-4684 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:127576 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)81661d885b9d708589e84a280d2796d4 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)34a94db0c76003e41d389cca7e4c0826 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)99ae95278bd95e30462a4fb2d12026c6 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)f8c334e84e585d7fa09d4d4b2d322041 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)c684a26e52cc44716354a4d15f530b4e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 22 |6 P:(DE-He78)e527f794b23172e769c8904180546f57 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-311 |2 G:(DE-HGF)POF3-300 |v Signalling pathways, cell and tumor biology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EMBO MOL MED : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EMBO MOL MED : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)A210-20160331 |k A210 |l Zelluläre Seneszenz |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B070-20160331 |k B070 |l Funktionelle Genomanalyse |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)A170-20160331 |k A170 |l Molekulare Stoffwechselkontrolle |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A210-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B070-20160331 |
| 980 | _ | _ | |a I:(DE-He78)A170-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|